ÂÜÀòÂÒÂ×

Keith Wycoff currently serves as the Vice President of Research at Planet Biotechnology, Inc., where the focus is on developing antibody-based therapeutic and preventative products using genetically modified green plants. Since 2010, Keith has also been the Research Director and Committee Chair for the Biotherapeutics/Genomics Committee at Life Science Angels, an organization dedicated to healthcare-focused angel investments. Additionally, Keith holds a board member position at Seal Rock Therapeutics, which is working on innovative treatments for NASH. Keith's academic background includes a PhD in Cellular and Developmental Biology from Harvard Kenneth C. Griffin Graduate School of Arts and Sciences, along with a BS and MS in Botany from the University of California, Davis. Prior to these roles, Keith gained valuable experience as a postdoctoral fellow at esteemed institutions including UCLA, Noble Foundation, and Salk Institute for Biological Studies.